Approval in the US of the second OTC product in a drug category typically doesn’t merit mention by the Food and Drug Administration commissioner.
Making opioid overdose treatment naloxone available OTC, however, isn’t a typical approval by the FDA.
HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation
Co-founder and CEO Michael Hufford says HRT hopes to distribute first commercial supply in early 2024. Firm is engaging additional funding partners to help make its affordable opioid overdose treatment more accessible.
